Abstract: A system for marking a plastic article with a computer readable matrix barcode associated with input material used to form the plastic article is provided. The system includes a barcode applicator positioned downstream of an article forming operation. The barcode applicator is configured to provide a computer-readable matrix barcode on a surface of the plastic article. The system further includes a controller communicatively coupled to the barcode applicator. The controller has one or more processors configured to collectively: receive tracing information for one or more ingredients of the input material used to form the plastic article; generate the computer-readable matrix barcode scannable to display the received tracing information for each ingredient; and transmit, to the barcode applicator, one or more commands instructing the barcode applicator to provide the generated computer-readable matrix barcode on the surface of the plastic article.

Abstract: A container for food items includes a base and an insert. The base includes a bottom panel and a peripheral bead having an inner sidewall extending upward from a perimeter of the bottom panel and a top wall extending outward from the inner sidewall. The inner sidewall and the bottom panel enclose, laterally and from below, a liquid collection reservoir. A base peripheral engagement surface includes the top wall and extends about the collection reservoir. The insert includes a support panel having drain apertures therein, an insert sidewall extending upward from a periphery of the support panel, and a flange extending outward from an upper end of the insert sidewall. An insert peripheral engagement surface includes at least a portion of the flange and is releasably interlockable with the base peripheral engagement surface when the insert is assembled to the base with the support panel overlying the collection reservoir.

Abstract: Techniques of configuring settings for automatic update of calendar items in an electronic calendar systems are disclosed herein. In one embodiment, a server can receive and store update configuration records indicating that a change to a start date, start time, an end date, an end time, or location of a meeting would render a meeting update actionable. Upon receiving an incoming meeting update, the server can determine whether the incoming meeting update contains a change to one of a start date, start time, an end date, an end time or location. If true, the server can automatically modify, without any input from the recipient, a scheduled meeting appointment in the calendar folder of the recipient according to the received incoming meeting update.

Abstract: A container for food items includes a base and an insert. The base includes a bottom panel and a peripheral bead having an inner sidewall extending upward from a perimeter of the bottom panel, a top wall extending laterally outward from an upper end of the inner sidewall, and an outer sidewall extending downward from a laterally outer edge of the top wall. At least a lower portion of the inner sidewall and the bottom panel enclose, laterally and from below, a liquid collection reservoir. The base includes a base peripheral engagement surface extending about the collection reservoir. The insert includes a support panel having an insert peripheral engagement surface releasably inter-lockable with the base peripheral engagement surface to assemble the insert to the base with the support panel overlying the collection reservoir. The support panel has at least one aperture for draining liquid from above into the collection reservoir.

Abstract: Methods of treating at least one cognitive symptom, e.g., at least one cognitive symptom associated with schizophrenia, comprising administering at least one compound chosen from Compound (I) and pharmaceutically acceptable salts thereof are disclosed. Also disclosed are methods of increasing D-serine levels, synaptic plasticity, and/or long-term potentiation comprising administering at least one compound chosen from Compound (I) and pharmaceutically acceptable salts thereof.

Abstract: Systems, methods, and computer program products for monitoring a health condition of a tool. Operational data is collected from a machine while the machine is operating in a predetermined manner with the tool in each of at least two known health conditions. A plurality of features is extracted from the operational data, a training dataset is generated from the extracted features, and an analytic model is trained using the training dataset. The analytic model can then be used to determine the health condition of the tool by providing features extracted from operational data received from one or more field machines to the analytic model. The analytic model may then determine a health condition of the tool in the field machine based on like features extracted from the operational data from the one or more field machines.

Abstract: The present invention is directed to pharmaceutical products, and to methods for the treatment of depression (e.g., major depressive disorder) and other diseases or disorders for which esketamine has a therapeutic benefit. In some embodiments, the methods are useful for the treatment of treatment-refractory or treatment-resistant depression or suicidal ideation. Methods of intranasal administration and devices for intranasal administration are also disclosed.

Abstract: The present invention provides methods for treating depression in a patient, comprising administering to the patient in need of the treatment a therapeutically effective amount of esketamine. In some embodiments, the depression is major depressive disorder or treatment resistant depression. In other embodiments, the therapeutically effective amount is clinically proven safe and/or effective. Also provided are methods to mitigate the risk or misuse or abuse of esketamine, instructions for use of the esketamine product, and methods for selling a drug product containing esketamine.

Abstract: Aspects of the present disclosure relate to improving runtime performance of equivalence checkers by a shift left process that uses an RTL lint tool to identify RTL code that can be a source of verification complexity for the downstream equivalence checker. The RTL code is further compared to a corresponding circuit model to determine a potential gate-level location of the potentially problematic RTL code. A weight can be calculated to represent a level of verification complexity that may be generated by the particular portion of the RTL code. Further, one or more recommendations can be generated by the RTL lint tool to prevent some of the verification complexity for the downstream equivalence checker.

Abstract: The present invention provides methods for treating depression in a patient, comprising administering to the patient in need of the treatment a therapeutically effective amount of esketamine. In some embodiments, the depression is major depressive disorder or treatment resistant depression. In other embodiments, the therapeutically effective amount is clinically proven safe and/or effective. Also provided are methods to mitigate the risk or misuse or abuse of esketamine, instructions for use of the esketamine product, and methods for selling a drug product containing esketamine.

Abstract: A container for food items includes a base and an insert. The base includes a bottom panel and a peripheral bead having an inner sidewall extending upward from a perimeter of the bottom panel, a top wall extending laterally outward from an upper end of the inner sidewall, and an outer sidewall extending downward from a laterally outer edge of the top wall. At least a lower portion of the inner sidewall and the bottom panel enclose, laterally and from below, a liquid collection reservoir. The base includes a base peripheral engagement surface extending about the collection reservoir. The insert includes a support panel having an insert peripheral engagement surface releasably inter-lockable with the base peripheral engagement surface to assemble the insert to the base with the support panel overlying the collection reservoir. The support panel has at least one aperture for draining liquid from above into the collection reservoir.

Abstract: The present invention provides methods for treating depression in a patient, comprising administering to the patient in need of the treatment a therapeutically effective amount of esketamine. In some embodiments, the depression is major depressive disorder or treatment resistant depression. In other embodiments, the therapeutically effective amount is clinically proven safe and/or effective. Also provided are methods to mitigate the risk or misuse or abuse of esketamine, instructions for use of the esketamine product, and methods for selling a drug product containing esketamine.

Abstract: The present invention provides methods of maintaining stable remission or stable response achieved by a patient with depression following administration of a therapeutically effective amount of esketamine during an initial administration phase, comprising continuing administration of a therapeutically effective amount of esketamine for at least five months during a subsequent administration phase. The present invention also provides methods for the long term treatment of depression in a patient, comprising administering to the patient in need of the treatment a clinically proven safe and clinically proven effective therapeutically effective amount of esketamine for at least six months. In some embodiments, the depression is major depressive disorder or treatment resistant depression.

Abstract: Cu-based bulk amorphous alloys in the quaternary Cu—Zr—Hf—Al alloy system are disclosed. A method of casting such alloys and articles comprising such alloys also are disclosed.

Abstract: A vacuum formed, tamper resistant container resists deformation of the sides thereof that might otherwise permit access to contents of the container without removal of the lid. Downward protruding lid features reinforce the wall of the container base, and buttress features included in the rim of the base extend from a base flange diagonally downward and inward to the inner rim of a recessed shelf, thereby resisting downward rotation of the wall beneath the lid protruding features. In embodiments, attachment tabs surrounded by frangible boundaries are incorporated in the lid and attached to the base by living hinges, such that removal of the lid requires breaking of the frangible boundaries and detachment of the lid from the attachment tabs. Pucker elements associated with the attachment tabs can cause the attachment tabs to pivot away from the lid when the attachment tabs are detached from the lid.

Abstract: Various exemplary drug delivery devices with on-board drug destruction, drug products utilizing the same, and methods of using drug delivery devices with on-board drug destruction are provided. In general, a nasal drug delivery device configured to dispense a drug therefrom into a nose includes a destruction mechanism configured to destroy drug contained in the drug delivery device. The destruction mechanism can be configured to destroy the drug before a first actuation of the drug delivery device to deliver the drug therefrom such that the destruction mechanism destroys substantially all of the drug contained in the drug delivery device. Alternatively or in addition, the destruction mechanism can be configured to destroy the drug after a first actuation of the drug delivery device to deliver the drug therefrom such that the destruction mechanism destroys substantially all of the drug remaining in the drug delivery device.

Abstract: The present invention provides methods of maintaining stable remission or stable response achieved by a patient with depression following administration of a therapeutically effective amount of esketamine during an initial administration phase, comprising continuing administration of a therapeutically effective amount of esketamine for at least five months during a subsequent administration phase. The present invention also provides methods for the long term treatment of depression in a patient, comprising administering to the patient in need of the treatment a clinically proven safe and clinically proven effective therapeutically effective amount of esketamine for at least six months. In some embodiments, the depression is major depressive disorder or treatment resistant depression.

Abstract: The present invention provides methods for treating depression in a patient, comprising administering to the patient in need of the treatment a therapeutically effective amount of esketamine. In some embodiments, the depression is major depressive disorder or treatment resistant depression. In other embodiments, the therapeutically effective amount is clinically proven safe and/or effective. Also provided are methods to mitigate the risk or misuse or abuse of esketamine, instructions for use of the esketamine product, and methods for selling a drug product containing esketamine.

Abstract: The present invention is directed to pharmaceutical products, and to methods for the treatment of depression (e.g., major depressive disorder) and other diseases or disorders for which esketamine has a therapeutic benefit. In some embodiments, the methods are useful for the treatment of treatment-refractory or treatment-resistant depression or suicidal ideation. Methods of intranasal administration and devices for intranasal administration are also disclosed.

Abstract: The present invention is directed to methods and dosing regimens for the treatment of depression (preferably, treatment resistant depression), for the treatment of depression in a suicidal patient, and/or for the treatment and/or prevention of suicidality (e.g. suicidal ideations).